1. Home
  2. FORA vs XBIT Comparison

FORA vs XBIT Comparison

Compare FORA & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forian Inc.

FORA

Forian Inc.

HOLD

Current Price

$2.16

Market Cap

67.3M

Sector

Technology

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.49

Market Cap

75.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FORA
XBIT
Founded
2014
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Pharmaceuticals and Biotechnology
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.3M
75.0M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
FORA
XBIT
Price
$2.16
$2.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
39.5K
22.3K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
25.00
N/A
EPS
N/A
N/A
Revenue
$30,256,919.00
N/A
Revenue This Year
$8.44
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
50.13
N/A
52 Week Low
$1.64
$2.09
52 Week High
$2.71
$3.61

Technical Indicators

Market Signals
Indicator
FORA
XBIT
Relative Strength Index (RSI) 60.16 51.65
Support Level $2.11 $2.15
Resistance Level $2.20 $2.69
Average True Range (ATR) 0.01 0.08
MACD -0.00 -0.01
Stochastic Oscillator 33.33 33.05

Price Performance

Historical Comparison
FORA
XBIT

About FORA Forian Inc.

Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: